Selank

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analog of the immune peptide tuftsin (a Thr-Lys-Pro-Arg fragment of the immunoglobulin G heavy chain), stabilized with a C-terminal Pro-Gly-Pro extension to slow enzymatic breakdown. It is most often discussed as an anxiolytic with additional anti-asthenic (anti-fatigue) and mild cognitive-supportive properties, and is typically administered as an intranasal solution. Unlike most research peptides, Selank has been studied in human patients, but almost entirely within the Russian regulatory and clinical-research system. Small comparative trials there have examined it in generalized anxiety disorder and neurasthenia, generally reporting anxiolytic activity comparable to benzodiazepines without the sedation, muscle relaxation, dependence, or withdrawal typically associated with that drug class. These studies are small, mostly open-label or active-comparator rather than large double-blind placebo-controlled trials, and have had limited independent international replication. Selank is reportedly registered as a medicine in Russia but is not approved by the FDA, EMA, or most other regulators. Outside Russia it is sold as a research chemical, typically labeled "for research use only." This entry summarizes the available science and community-reported practice for reference only; it is not medical advice and does not endorse human use.